MarketCapExport financials
Landos Biopharma (LABP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Landos Biopharma Balance Sheet 2023-2011 | LABP
Brief overview of Landos Biopharma's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2019 to 2023.
Assets declined from $50.5 million to $38 million, or -24.6%. The contraction calls for context such as disposals, restructuring or weaker operations.
Growth in the asset base was not matched by liabilities: -24.6% versus -91.8%. The balance sheet moved in a more conservative direction.
Internal capital represents 83.6% of the balance sheet, previously . This is a strong capital position.
The accumulated result is -$155.4 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Balance sheet takeaway
Landos Biopharma retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet Landos Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -2.42 M | -9.81 M | -359 K | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 73 M | - | - | - | - | - | - | - | - |
Total Current Liabilities |
6.25 M | 6.12 M | 16.6 M | 11 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.25 M | 6.12 M | 16.6 M | 11.3 M | 76.1 M | 1.8 M | - | - | - | - | - | - | - |
Retained Earnings |
-155 M | -133 M | -94.2 M | -55.7 M | -25.6 M | -9.14 M | - | - | - | - | - | - | - |
Total Assets |
38 M | 45.3 M | 92.9 M | 30.3 M | 50.5 M | 2.8 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
37.5 M | 36.6 M | 8.3 M | 2.42 M | - | - | - | - | - | - | - | - | - |
Book Value |
31.8 M | 39.1 M | 76.3 M | 19 M | -25.6 M | 1 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
31.8 M | 39.1 M | 76.3 M | -54 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Landos Biopharma
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Liabilities |
6.74 M | 5.57 M | 3.02 M | 4.16 M | 6.12 M | 5.48 M | 6.51 M | 15.5 M | 16.6 M | 11.2 M | 12.7 M | 9.03 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-164 M | -149 M | -143 M | -139 M | -133 M | -128 M | -120 M | -109 M | -94.2 M | -74.1 M | -61.4 M | -65.5 M | -55.7 M | -55.7 M | -55.7 M | -55.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
29.9 M | 43.2 M | 46.3 M | 51.2 M | 45.3 M | 49.5 M | 58 M | 77.6 M | 92.9 M | 105 M | 118 M | 110 M | 30.3 M | 30.3 M | 30.3 M | 30.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
29 M | 42.4 M | 44 M | 45.2 M | 36.6 M | 28.9 M | 19.2 M | 11.3 M | 8.3 M | 17.9 M | 18.7 M | 8.57 M | 2.42 M | 2.42 M | 2.42 M | 2.42 M | 9.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
23.2 M | 37.7 M | 43.3 M | 47 M | 39.1 M | 44 M | 51.5 M | 62.1 M | 76.3 M | 93.9 M | 106 M | 101 M | 19 M | 19 M | 19 M | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
23.2 M | 37.7 M | 43.3 M | 47 M | 39.1 M | 44 M | 51.5 M | 62.1 M | 76.3 M | 93.9 M | 106 M | 101 M | -54 M | -54 M | -54 M | -54 M | -25.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Landos Biopharma, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
